文献速递炎症性肠病

炎症性肠病患者的2019新型冠状病毒病(COVID-19)

2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases.
PubMed 文献 · Aliment Pharmacol Ther · 2020-06-07

该病例系列纳入1918例IBD患者中实验室确诊COVID-19的12例,年龄52岁,75%女性,58.3%为克罗恩病。IBD患者COVID-19调整发病率低于一般人群(OR 0.74,95%CI 0.70-0.77;P<0.001),相关死亡率相似(OR 0.95,95%CI 0.84-1.06;P=0.36);腹泻常见,部分为首发或唯一症状。

要点

  • IBD患者COVID-19风险未增加,死亡率与一般人群相似。
  • 腹泻在IBD合并COVID-19中常见,可为首发或唯一症状。
  • 免疫调节剂/生物制剂维持治疗者占58%,需结合病情评估。

核心结论

  • IBD患者COVID-19风险及相关死亡率与一般人群相比未增加。
  • 许多IBD患者以腹泻为首发症状,有时为唯一症状。

研究设计与样本

  • 比较IBD患者与马德里地区一般人群的年龄调整累积发病率。

主要发现

  • 12例IBD患者平均年龄52岁,75%为女性,58.3%为克罗恩病。
  • 7例(58%)接受免疫调节剂/生物制剂维持治疗,其中4例(33%)为联合治疗。
  • 8例(66%)需住院(1例入ICU,2例死亡),4例居家隔离。
  • 9例出现腹泻,每日4-10次稀便(均值5.4,SD 1.6);5例(42%)腹泻为首发症状,2例腹泻为唯一首发症状。
  • IBD患者COVID-19累积发病率为6.2/1000;调整后发病率比一般人群低(OR 0.74,95%CI 0.70-0.77;P<0.001),相关死亡率相似(OR 0.95,95%CI 0.84-1.06;P=0.36)。

临床怎么用

  • 对IBD患者出现腹泻应警惕COVID-19,尤其腹泻可为首发或唯一症状。
  • IBD患者COVID-19风险未增加,免疫调节剂/生物制剂维持治疗需个体化评估。

局限性

  • 为病例系列研究,样本量小(12例),来自单一地区。
  • 未报告对照组详细特征及潜在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on patients with inflammatory bowel diseases (IBD) who have had 2019 novel coronavirus (SARS-CoV-2) disease (COVID-19) are needed. AIMS: To report the clinical characteristics, including gastrointestinal symptoms, of COVID-19 in IBD patients, and to assess the risk of COVID-19 in IBD. METHODS: This case series included consecutive IBD patients with laboratory-confirmed COVID-19. Age-adjusted cumulative incidences were compared with the general population in the Madrid region. RESULTS: Through April 8, 12 of 1918 IBD patients were diagnosed with COVID-19. The average age was 52 years, 75% of the patients were female and 58.3% had Crohn's disease. Seven patients (58%) were on maintenance treatment with immunomodulators/biologics, of these four with combined therapy (33%). Eight patients (66%) required hospitalisation (one intensive care unit admission, and two deaths), and four patients were isolated at home. Nine patients had diarrhoea ranging between 4 and 10 loose stools per day (mean 5.4, SD 1.6). In five patients (42%) diarrhoea was a presenting symptom. In two patients, diarrhoea was the only symptom at debut. Cumulative incidence of COVID-19 was 6.2 per 1000 IBD patients. IBD patients had a lower adjusted incidence ratio of COVID-19 (OR 0.74, 95% CI 0.70-0.77; P < 0.001), and a similar associated mortality ratio (OR 0.95, 95% CI: 0.84-1.06; P = 0.36), compared with the general population. CONCLUSIONS: IBD patients do not have an increased risk of COVID-19 and associated mortality compared with the general population. In many IBD patients, diarrhoea was a presenting symptom, and sometimes, was the only symptom at onset of COVID-19.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Taxonera C, Sagastagoitia I, Alba C, et al. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2020. PMID: 32359205. doi:10.1111/apt.15804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。